SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES

The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL- 17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX). 本发明涉及选择性还原由哺乳动物细胞重组产生的IL-17抗体或其抗原结合片段制品(例如苏金单抗抗体制品)中的CysL97的方法。本发明还提供了通过这些方法生产的IL-17抗体或其抗原结合片段的纯化制品，例如苏金单抗的纯化制品，其中该制品中的完整IL-17抗体或其抗原结合片段(例如苏金单抗)的含量较高，例如通过十二